What did Iperion Limited announce?

Iperion Limited (NZX: IPR) filed “2026 Annual Meeting Presentation Material” with NZX on 30 September 2026, as an agm announcement.

From the announcement:“For shareholders who have not voted yet via MUFG, but still wish to do so after the meeting, please forward your completed voting form to john.cilliers@iperion.co.nz by no later than 4pm today.”
When was it filed?
30 September 2026
Where is the original?
NZX announcement
Iperion Limited/Announcement
Iperion Limited logo

2026 Annual Meeting Presentation Material

AGM30 September 2026IPRReal Estate

Iperion Limited
Annual Meeting

30 September 2026

Agenda
•

Welcome and Introductions

•

Formalities

•

Presentation to Shareholders

•

Q&A Discussion

•

Resolutions

•

Appendix: Additional information on Pathoglaze

Formalities
•

Attendance of the virtual meeting has been left open for all

interested to be able to attend.

•

The meeting is recorded.

•

To ensure that voting is accounted for correctly, all votes will

be required to be submitted electronically. For shareholders

who have not voted yet via MUFG, but still wish to do so after

the meeting, please forward your completed voting form to

john.cilliers@iperion.co.nz by no later than 4pm today.

(contact John if you need a form)

Review of the year ended 31 March 2026
•

No interest income in 2026 as cash was

not placed in term deposits so as to be

available to cover costs for an

anticipated sales order.

•

Fixed outsource manufacturing plant fee

fully discounted for 2026.

•

Admin expenses lower in 2026 with

savings made in travel costs and audit

fees. Savings were partially offset by

increase in stock exchange fees.

•

Impairment expense was on trademark

intangibles. There were no costs for

trademarks in 2026.

•

There were no changes in the number

of shares on issue.

2025

$

2026

$

20,38210Interest income

150,0000

Outsource

Manufacturing Plant

317,781294,605Administrative expenses

8,2840Impairment expense

455,683294,595Net loss

348,39853,803Net assets

425,341155,492Cash and Term deposits

Cash Reserves and Financial Support

Financial support:


The Company entered into a loan agreement with Elitesoft Asia, a company

related to Mr Chang Ku EE, the majority shareholder and a director of the

Company, pursuant to which Elitesoft provides a loan facility of $250,000 to

the Company at 8% interest (Hong Kong Monetary Authority Base Rate + 4%),

which can be increased to US$1,000,000 subject to approval by Iperion’s

shareholders.


Mr EE confirmed that he will provide financial support to the Company, if

required to meet its working capital obligations and liabilities as they fall due,

for at least a period of 12 months from the date of approval of the Company’s

financial statements (30 Jun 2026).


Initiatives to conserve cash reserves:


Since January 2026, payment on 50% of directors’ fees and 33% of the

management fee are being deferred, until sufficient sales are achieved to

move the company to a positive cash flow position.

Manufacturing Facilities

Outsource Manufacturing Plant:


The fixed annual fee on the Pathoglaze outsource manufacturing plant fees for

the financial year to March 2026 was fully discounted by the vendor and will

be fully discounted through to March 2028.


The vendor is in the process of moving the manufacturing plant from Malaysia

to Singapore. The equipment is currently in storage. Sufficient Pathoglaze

compound has already been manufactured and is available to fill sales orders

until the plant is setup again. In the interim, ongoing product development is

being supported from the Licensor’s facilities in Singapore where smaller

product batches can also be manufactured if needed.


In recognition of the collaborative efforts undertaken between the inventor of

Pathoglaze and Iperion, agreement was reached to permanently waive the

customer and revenue performance targets under Iperion’s exclusive world-

wide license.

Progress and current activities

Work undertaken during the year ending March 2026 mainly focused on

completing the development of Pathoglaze infused polymer jute bags

used for shipping cocoa and coffee beans. This work was being

undertaken in collaboration with a multinational chocolate manufacturer


Product tests and trials for specific applications continue with potential

customers as they arise.


With support from Mr EE, directors have also been investigating a range

of alternative product and sales opportunities for the company.

Questions

Resolution 1
John Cilliers retires by rotation in accordance with the Company’s constitution and

NZX

Listing Rule 2.7.1

. Being eligible, John offers himself for re-election. The Board considers

John to be an Independent Director. Accordingly, the shareholders of the Company are

requested to consider and, if thought fit, pass the following resolution as an Ordinary

Resolution.

Ordinary Resolution: That that John Cilliers, who retires in accordance with NZX Listing

Rule 2.7.1, and being eligible for re-election, be re-elected as a director of IPR.

Abstain

% of Issued

Capital

AgainstOpenFor

0

78.98%9,0004,000406,661,251

Votes

143Holders

0.00%0.00%100.00%

Percentage

Proxies:

Resolution 2
Kuan Chong Ng (“KC”), retires by rotation in accordance with the Company’s constitution.

Being eligible, KC offers himself for re-election at the Annual Meeting. The Board does not

consider Mr Ng to be an Independent Director. Accordingly, the shareholders of the Company

are requested to consider and, if thought fit, pass the following resolution as an Ordinary

Resolution.

Ordinary Resolution: That Kuan Chong Ng, who retires in accordance with NZX Listing Rule

2.7.1, and being eligible for re-election, be re-elected as a director of IPR.

Abstain

% of Issued

Capital

AgainstOpenFor

0

78.98%9,0004,000406,661,251

Votes

143Holders

0.00%0.00%100.00%

Percentage

Proxies:

Resolution 3
BDO is automatically reappointed at the annual meeting as the auditor of the Company

under section 207T of the Companies Act. This resolution authorises the Board to fix the

fees and expenses of the auditor.

Ordinary Resolution: That the Board is authorised to fix BDO Auckland’s fees and

expenses as the auditor of IPR.

Abstain

% of Issued

Capital

AgainstOpenFor

398,528,343

1.58%04,0008,141,908

Votes

043Holders

0.00%0.05%99.95%

Percentage

Proxies:

Thank you

Pathoglaze is a durable, high potency, anti-
microbial product capable of being

incorporated into raw materials for other

products at the point of manufacture.

For example it can be incorporated in plastics

masterbatch powders prior to product

moulding or it can be applied to existing

products as a thin film coating.

•
Pathoglaze infused polymer jute bags

used for shipping cocoa and coffee

beans.

•

These bags reduce losses that result

from microbial contamination during

shipping and transport.

PATHOGLAZE®Hyperion is a high-potency zinc-basedantimicrobial additive.
Having a core shell- nanopillar morphological structure.

It can kill, reduce and prevent the growth of harmful microorganism (e.g.: bacteria,

virus, fungi, algae).

Having an antimicrobial activity up to 99.9 % (test method: ISO22196).

Can be seamlessly incorporated in a wide range of end-use products during

the manufacturing process without interfering with the actual manufacturing

setup.

HYPERIONAdditive

–greyish powder

Fine Powder (Additives)

UNIQUE MECHANISM
Does not rely on external

stimulus light energy to

generate ROS.

SAFETY

Safe to be used as additive in

food packaging polymers.

*Tested in compliance with

US FDA and EU regulation.

EFFICACY

99.9 % effective against

microorganisms, even

at low use levels.

STABILITY

It has thermal resistance

up to 410 °C and is

insoluble in water.

FLEXIBILITY

Seamless incorporation

into a wide range of

applications.

Key Features

Additives

PATHOGLAZE

PLASTICS AND POLYMERS
(Food-grade and non food-grade)

List of polymers compatible with PATHOGLAZE:

i. Commodity thermoplastics (i.e.: PE, PS)

ii. Engineering thermoplastics (i.e.: PC, ABS, PC/ABS,

PA)

iii. Thermosets (i.e.: epoxy)

iv. Synthetic rubber (i.e.: NBR and EPDM)

PAINTS AND COATINGS

By Applications

Area of Application

PATHOGLAZE®

Our PATHOGLAZE®additives are compatible with almost all plastics and
polymer materials (i.e.: trial for PP, PC and ABS).

With 0.5%of PATHOGLAZE loading = 99.9%of antimicrobial activity

(ISO22196)

Seamlessly compound in polymer using the existing process

Embedded within the polymer compound itself, delivering continuous

protection against microbes without affecting gloss or matte surfaces, color,

durability, and properties.

PP compound with 0.5% of

PATHOGLAZE

PASS

In-polymer Food Contact Test according to

-US FDA 21 CFR 177.1520

PASS

Migration Test according to Commission Regulation (EU)

-EU 10/2011 Article 3 of European Regulation

1935/2004*

Polymer compound

P o t e n t i a l
PATHOGLAZE

APPLICATION

Cutting boards, wall coverings, appliances,

toilet seats, flooring, mattresses

Housewares:

PVC blinds, car interiors, packaging, signs,

electronics, seating

Commercials:

yoga mats, footwear, duffle bags,

sports equipment

Fitness:

flooring, vinyl siding, windows, insulation,

piping, roofing membranes

Construction materials:

business supplies, medical devices, seating,

countertops, storage

Healthcare:

i. Prevents the growth of bacteria and fungi on the surface.
ii. Reduces bacteria in the surrounding area, and reduces the spread of infection.

iii. Prolongs food shelf life.

iv. Promotes product reusability and recyclability.

Packaging (primary & secondary)

Thin film is a layer of material with a thickness ranging from a
nanometer to micrometer on the surface of a substrate.

Harnessing the potential of zinc, PATHOGLAZE thin film is a

zinc-based thin-film coating.

PATHOGLAZE

®

thin film series is particularly targeted for

coating on non-porous surfaces i.e.; glass windows, solar

panels, touch-sensitive displays, etc. where transparency

coating is a key consideration.

Thin Film

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • PHL — Promisia Healthcare Limited: ASM 2026 Presentation
    2026-08-27

    “1 Annual Shareholders’ Meeting 27 August 2026 2 Board Rhonda Sherriff Chair and Independent Director Thomas Brankin Non-Independent Director 1 Tony Mortensen Non-Independent Director Jill Hatchwell Independent Director Craig Percy Independent Director Francisco Rodriguez Ferrer…”

  • RUA — Rua Bioscience Limited: Rua Releases Annual Report for Year Ended 30 June 2026
    2026-09-22

    “74Financial statements Research and Development (R&D) Loss Tax Credit repayment The Company claimed R&D Loss Tax Credits in the 2019 and 2020 income years under the Income Tax Act 2007. Under the Act, these credits become repayable in certain circumstances where shareholder con…”

  • IPL — Investore Property Limited: Interim Results HY27
    2026-11-16

    “Corporate Directory Board of Directors Mike Allen (Chair) Gráinne Troute Adrian Walker Ross Buckley (SIML-appointed Director) D avid Green (SIML-appointed Director, appointed 3 June 2026) T im Storey (SIML-appointed Director, ceased 3 June 2026) Registered Office L evel…”